Dermatitis News

Lower levels of retinoid receptor expression correlated to hand eczema, according to a poster presented at American Academy of Dermatology virtual meeting.

Nearly 70% of pediatric patients with periorificial dermatitis who underwent topical calcineurin inhibitor monotherapy showed a complete response, according to a study.

Kymera Therapeutics has initiated a non-interventional trial evaluating IRAK4 expression in hidradenitis suppurativa and atopic dermatitis, according to a press release.

The FDA has approved triamcinolone acetonide ointment for the treatment of inflammatory and pruritic manifestations of dermatoses, Strides Pharma Science Limited announced in a press release.

Dupixent has been approved by the FDA for the treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years, Regeneron Pharmaceuticals and Sanofi announced in a press release.

Dupilumab showed rapid improvement in itch in patients with moderate to severe atopic dermatitis, according to an analysis of four phase 3 trials.

A daily regimen of oral serlopitant was associated with a significant reduction in pruritus in a small cohort of patients with mild to moderate psoriasis, according to a study.

Ruxolitinib was associated with clinically meaningful improvement in itch in a cohort of patients with atopic dermatitis, according to a study.

Cyclosporine and dupilumab may show more effectiveness up to 16 weeks in treating atopic dermatitis than methotrexate and azathioprine, according to a systematic review and network meta-analysis.

As the world continues to struggle with the COVID-19 pandemic, new symptoms of the virus continue to be identified. One such symptom, purple or red lesions on the toes and hands, has been dubbed “COVID toes” and has gained attention over recent weeks.